Results 1 to 10 of about 1,751 (155)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate [PDF]

Nature and Science of Sleep, 2023
Logan D Schneider,1 Anne Marie Morse,2 Michael J Strunc,3 Joyce K Lee-Iannotti,4 Richard K Bogan5 1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA; 2Janet Weis Children’s Hospital, Geisinger ...
Schneider LD, Morse AM, Strunc MJ, Lee-Iannotti JK, Bogan RK   +4 more
doaj   +5 more sources

Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations [PDF]

Neurology and Therapy
Introduction Low-sodium oxybate (LXB) is approved for treatment of narcolepsy in patients aged 7 years and older and treatment of idiopathic hypersomnia in adults. LXB contains the same active moiety with 92% less sodium than sodium oxybate (SXB). As the
Anne Marie Morse, Richard K. Bogan, Asim Roy, Michael J. Thorpy   +3 more
doaj   +4 more sources

A Patient-centric Clinical Trial Design to Comprehensively Evaluate Low-Sodium Oxybate in People with Idiopathic Hypersomnia or Narcolepsy [PDF]

Neurology and Therapy
Introduction Low-sodium oxybate (LXB; Xywav®) is approved to treat idiopathic hypersomnia in adults and excessive daytime sleepiness or cataplexy in individuals aged ≥ 7 years with narcolepsy.
Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Emily C. Barker, Marisa Whalen, Jessica K. Alexander, Sarah Akerman, David T. Plante   +8 more
doaj   +3 more sources

Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy. [PDF]

CNS Drugs, 2023
The safety and efficacy of low-sodium oxybate (LXB; Xywav®) were established in a randomized, double-blind, placebo-controlled, phase 3 withdrawal study in adults with narcolepsy with cataplexy; however, the longer-term safety profile has not yet been examined.
Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ.   +4 more
europepmc   +3 more sources

Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy. [PDF]

Hypertension
BACKGROUND: People with narcolepsy are at increased risk for hypertension and cardiovascular disease; excessive sodium intake is linked to both. METHODS: We studied patients with narcolepsy and office systolic blood pressures (BPs) of ...
White WB, Kovacs RJ, Alexander JK, Baranak C, Nichols DA, Fuller DS, Dai J, Whalen M, Ajayi A, Hutchinson B, Dauvilliers Y, Somers VK.   +11 more
europepmc   +2 more sources

Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial [PDF]

BMJ Open
Introduction Cerebral amyloid angiopathy (CAA) is caused by the accumulation of amyloid-beta (Aβ) in the cerebrovasculature. The glymphatic system is thought to be involved in the clearance of cerebral waste products, including Aβ.
Marianne A A van Walderveen, Marcel M Verbeek, Erik W van Zwet, Marieke J H Wermer, Adriaan C G M van Es, Matthias J P van Osch, Rolf Fronczek, Ellis S van Etten, Lydiane Hirschler, Sanne E Schriemer, Gert Jan Lammers, Eric J Liebler, Annelies M Slats   +12 more
doaj   +2 more sources

Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. [PDF]

J Clin Sleep Med, 2023
To evaluate 6-month efficacy and safety of low-sodium oxybate in people with idiopathic hypersomnia during an open-label extension period (OLE) of a phase 3 clinical trial.Efficacy measures included the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Patient Global Impression of Change (PGIc), Functional Outcomes of Sleep ...
Morse AM, Dauvilliers Y, Arnulf I, Thorpy MJ, Foldvary-Schaefer N, Chandler P, Chen A, Hickey L, Black J, Bogan RK.   +9 more
europepmc   +3 more sources

Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav study. [PDF]

J Clin Sleep Med
Low-sodium oxybate (LXB; calcium, magnesium, potassium, and sodium oxybates; Xywav) contains the same active moiety as high-sodium oxybates (SXBs; SXB [Xyrem] and fixed-dose SXB [Lumryz]), with 92% less sodium, and is approved in the United States for treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with ...
Macfadden W, Leary EB, Fuller DS, Kirby MT, Roy A.   +4 more
europepmc   +3 more sources

Comparative efficacy of sodium oxybate versus placebo on improvement of nighttime sleep in adult patients with narcolepsy: A systematic review and meta-analysis [PDF]

Sleep Medicine: X
Background: Narcolepsy, a central hypersomnolence disorder, disrupts sleep regulation. Sodium oxybate, a CNS (central nervous system) depressant, is widely used as a treatment, but there are surprisingly very few rigorous studies comparing its ...
Adina Arshad, Muhammad Abdul Muqtadir Qureshi, Muhammad Abdullah Masood, Hafiz Shahbaz Zahoor, Ayesha Nazakat, Anfal Fatima, Javed Iqbal   +6 more
doaj   +2 more sources

Sodium Oxybate-Induced secondary mania with psychotic symptoms: a case report and literature review [PDF]

European Psychiatry
Introduction Sodium oxybate, an effective treatment for narcolepsy-associated daytime sleepiness and cataplexy, has been extensively. Despite its therapeutic benefits, sodium oxybate is not without its risks, and adverse psychiatric effects have been ...
C. Cárdenes Moreno, S. Yelmo-Cruz, I. Pérez Sagaseta de Ilurdoz, J. J. Tascón-Cervera, G. P. González-Rodríguez, M. Gallego-Restrepo   +5 more
doaj   +2 more sources